Market Insight - Can ageing be slowed to prevent disease?
This article was originally published in Scrip
The idea of extending the human lifespan has long fascinated the public and challenged scientists. Funding for research into ageing processes, and the R&D of therapeutics to slow them, is increasing. Recent findings suggest that progress has been made, motivated in part by the rapid growth of elderly populations that might benefit from such advances. Furthermore, economists predict that many countries may face bankruptcy by 2050 (or earlier) because of rising healthcare expenditures associated with care of the elderly.
You may also be interested in...
Life cycle management approaches include the development of new formulations of drugs (for example, advanced delivery systems, metabolites or isomers) in order to improve the clinical performance and extend the patent life of well established drugs. In today's cost-containment environment, however, payers and physicians are challenging this strategy by asking tougher questions, such as ‘is the new drug superior to its predecessor?" and ‘if there is a benefit, is it marginal, or is it large enough to justify a significantly higher price, when compared with all prescription antidepressants?'
The repositioning of drugs for new clinical indications is becoming an increasingly prominent development strategy because it can reduce development risk as well as both the time and investment required to bring a product to market. Previously exclusive to pharmaceutical companies working to expand the applications of their marketed drugs, repositioning (also known as repurposing, reprofiling, therapeutic switching, or developing 'second use' indications) has emerged as an industry in its own right, encompassing both technology and drug companies. Today, companies involved in repositioning are charging for their services, establishing collaborative agreements and using the strategy to develop their own pipelines.